Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 467-474

  Schneider, T ^a   Sevko, A ^b   Heussel, C P ^c   Umansky, L ^d   Beckhove, P ^d   Dienemann, H ^c   Safi, S ^c   Utikal, J ^b   Hoffmann, H ^c   Umansky, V ^b  

^a Department of Abdominal   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chronic inflammatory factors; Myeloid derived suppressor cells; Non small cell lung cancer; Radiofrequency ablation

Indexed keywords

BIOLOGICAL MARKER; CARBON TETRACHLORIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; MALE; MYELOID DERIVED SUPPRESSOR CELL; NECROSIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; THORACOSCOPY; BLOOD; BONE MARROW CELL; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; CELL COUNT; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84929514769     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12596     Document Type: Article

References (38)

1. Hiraki T, Gobara H, Mimura H, Matsui Y, Toyooka S, Kanazawa S. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2011; 142:24-30.
2. Lencioni R, Crocetti L, Cioni R et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the rapture study). Lancet Oncol 2008; 9:621-8.
3. Clasen S, Krober SM, Kosan B et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer 2008; 113:3121-9.
4. Schneider T, Reuss D, Warth A et al. The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. Eur J Cardiothorac Surg 2009; 39:968-73.
5. Nierkens S, den Brok MH, Ruers TJ, Adema GJ. Radiofrequency ablation in cancer therapy: tuning in to in situ tumor vaccines. In: Keisari Y ed. Tumor ablation: effects on systemic and local anti-tumor immunity and on other tumor-microenvironment interactions. Dordrecht: Springer, 2013:39-59.
6. Wissniowski TT, Hansler J, Neureiter D et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the vx2 hepatoma in rabbits. Cancer Res 2003; 63:6496-500.
7. den Brok MH, Sutmuller RP, van der Voort R et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024-9.
8. den Brok MH, Sutmuller RP, Nierkens S et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896-905.
9. Chen Y, Williams J, Ding I et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; 12:26-33.
10. Nomura M, Yamakado K, Nomoto Y et al. Complications after lung radiofrequency ablation: risk factors for lung inflammation. Br J Radiol 2008; 81:244-9.
11. Rughetti A, Rahimi H, Rossi P et al. Modulation of blood circulating immune cells by radiofrequency tumor ablation. J Exp Clin Cancer Res 2003; 22:247-50.
12. Hansler J, Wissniowski TT, Schuppan D et al. Activation and dramatically increased cytolytic activity of tumor specific t lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006; 12:3716-21.
13. Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013; 57:1448-57.
14. Zerbini A, Pilli M, Penna A et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific t-cell responses. Cancer Res 2006; 66:1139-46.
15. Zerbini A, Pilli M, Fagnoni F et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008; 31:271-282.
16. Schell SR, Wessels FJ, Abouhamze A, Moldawer LL, Copeland EM, III. Pro- and antiinflammatory cytokine production after radiofrequency ablation of unresectable hepatic tumors. J Am Coll Surg 2002; 195:774-81.
17. Kallio R, Sequeiros R, Surcel HM, Ohtonen P, Kiviniemi H, Syrjala H. Early cytokine responses after percutaneous magnetic resonance imaging guided laser thermoablation of malignant liver tumors. Cytokine 2006; 34:278-83.
18. Evrard S, Menetrier-Caux C, Biota C et al. Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. Gastroenterol Clin Biol 2007; 31:141-5.
19. Jansen MC, van Wanrooy S, van Hillegersberg R et al. Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors. Eur J Surg Oncol 2008; 34:662-7.
20. Kawakami T, Hoshida Y, Kanai F et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005; 5:4287-95.
21. Fietta AM, Morosini M, Passadore I et al. Systemic inflammatory response and downmodulation of peripheral CD25+FoxP3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol 2009; 70:477-86.
22. Lanuti M, Sharma A, Digumarthy SR et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137:160-6.
23. Pennathur A, Luketich JD, Abbas G et al. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 2007; 134:857-64.
24. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53.
25. Peranzoni E, Zilio S, Marigo I et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-44.
26. Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 2011; 15:1127-37.
27. Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009; 9:375-383.
28. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLOS ONE 2011; 6:e17479.
29. Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of circulating angiogenic biomarkers from patients in two Phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer 2012; 106:1153-9.
30. Zhao L, Ji W, Zhang L et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010; 5:521-5.
31. Ali MY, Grimm CF, Ritter M et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 2005; 43:817-22.
32. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255-63.
33. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75.
34. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107-15.
35. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68.
36. Arihara F, Mizukoshi E, Kitahara M et al. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62:1421-30.
37. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010; 21:41-8.
38. Schneider T, Kimpfler S, Warth A et al. Foxp3(+) regulatory Tcells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011; 6:432-8.